Neurology Central

Aducanumab trials to be discontinued for Alzheimer’s disease


Biogen (MA, USA) and Eisai (Tokyo, Japan) have announced the decision to discontinue the global Phase III trials, ENGAGE and EMERGE, of aducanumab for people with mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s disease dementia.

The decision to stop the trials has been reported to be based on results of a futility analysis conducted by an independent data monitoring committee, which indicated that the trials were unlikely to meet their primary endpoint upon completion. The recommendation to stop the studies was not based on safety concerns.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.